Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Advanced Breast Cancer 4Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Solid Malignancies 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Pancreatic Neoplasms 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1

Interventions

lutetium Lu 177 dotatate 2Sunitinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Everolimus 2sargramostim 1sapanisertib 1pentetreotide 1pasireotide 1napabucasin 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1fludarabine phosphate 1aflibercept 1Taxes 1Sorafenib 1Salts 1Paclitaxel 1Oxaliplatin 1Octreotide 1Leucovorin 1Irinotecan 1Interleukin-13 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Islet Cell × Fulvestrant × Clear all
NCT06663072 2026-01-09

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago

Phase 1 Recruiting
25 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡